X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
RGN-259 (timbetasin acetate) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.
Lead Product(s): Timbetasin Acetate
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
RGN-259 (timbetasin acetate) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.
Lead Product(s): Timbetasin Acetate
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: HLB Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022
Details:
RGN-259 (timbetasin acetate) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.
Lead Product(s): Timbetasin Acetate
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: HLB Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
RGN-259 (timbetasin acetate) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.
Lead Product(s): Timbetasin Acetate
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
RGN-259, a Tβ4-based sterile and preservative-free eye drop, as a novel treatment for dry eye and neurotrophic keratitis (NK), a persistent corneal defect caused by diabetes and herpes zoster virus, among other pathologies.
Lead Product(s): Timbetasin Acetate,Undisclosed
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
The purpose of a pre-BLA meeting is to discuss with FDA the format, content, and acceptability of RGN-259, a sterile, preservative-free eye drop that has been shown to reduce symptoms of dry eye syndrome based on the results to date.
Lead Product(s): Timbetasin Acetate
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: ReGenTree
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2021
Details:
RGN-259 or Thymosin Beta 4 is timbetasin, a small peptide with G actin-sequestering action. It is associated with induction of angiogenesis, accelerated wound healing and increased metastatic potential of tumor cells.
Lead Product(s): Timbetasin Acetate
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2021
Details:
Acquisition of GtreeBNT by HLB Group, would speed up the clinical trials currently in progress and allow the company to focus on new drug approval. RGN-259 will remain a priority for the company.
Lead Product(s): Timbetasin Acetate
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: HLB Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 27, 2021
Details:
The funding will provide working capital through the first quarter of 2021 and while we await the completion of our phase 3 dry eye clinical trial (ARISE-3) expected later this year.
Lead Product(s): Timbetasin Acetate
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: ReGenTree
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
